The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Timeline
X Demographics
Mendeley readers
Attention Score in Context
Title |
Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
|
---|---|
Published in |
Frontiers in oncology, August 2022
|
DOI | 10.3389/fonc.2022.918499 |
Pubmed ID | |
Authors |
Stefano Kim, Jihane Boustani, Dewi Vernerey, Véronique Vendrely, Ludovic Evesque, Eric Francois, Laurent Quero, Francois Ghiringhelli, Christelle de la Fouchardière, Laëtitia Dahan, Oliver Bouché, Benoist Chibaudel, Farid El Hajbi, Chloé Vernet, Magali Rebucci-Peixoto, Alexandra Feuersinger, Christophe Maritaz, Christophe Borg |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 6 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 1 | 17% |
Student > Bachelor | 1 | 17% |
Unknown | 4 | 67% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 1 | 17% |
Unknown | 5 | 83% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2022.
All research outputs
#21,310,332
of 26,170,906 outputs
Outputs from Frontiers in oncology
#11,651
of 22,913 outputs
Outputs of similar age
#322,408
of 434,610 outputs
Outputs of similar age from Frontiers in oncology
#1,014
of 1,794 outputs
Altmetric has tracked 26,170,906 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 434,610 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,794 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.